NVNO
Income statement / Annual
Last year (2023), enVVeno Medical Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, enVVeno Medical Corporation's net income was -$23.52 M.
See enVVeno Medical Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31,243.00
|
$186,552.00
|
$422,111.00
|
$785,912.00
|
$0.00
|
$236,500.00
|
| Cost of Revenue |
$546,000.00 |
$525,000.00 |
$452,909.00 |
$383,972.00 |
$0.00 |
$0.00 |
$419,659.00 |
$810,294.00 |
$125,423.00 |
$132,315.00 |
| Gross Profit |
-$546,000.00 |
-$525,000.00 |
-$452,909.00 |
-$383,972.00 |
$31,243.00 |
$186,552.00 |
$2,452.00 |
-$24,382.00 |
-$125,423.00 |
$104,185.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
1 |
1 |
0.01 |
-0.03 |
0 |
0.44 |
| Research and Development
Expenses |
$13.58 M
|
$9.91 M
|
$5.73 M
|
$4.25 M
|
$2.21 M
|
$1.24 M
|
$649,736.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.66 M
|
$15.02 M
|
$11.16 M
|
$4.88 M
|
$4.91 M
|
$6.48 M
|
$5.46 M
|
$4.63 M
|
$1.29 M
|
$1.06 M
|
| Other Expenses |
$0.00 |
$0.00 |
$33,272.00 |
-$215,906.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$25.24 M |
$24.93 M |
$16.89 M |
$9.14 M |
$7.12 M |
$7.72 M |
$6.11 M |
$4.63 M |
$1.29 M |
$1.06 M |
| Cost And Expenses |
$25.24 M |
$24.93 M |
$16.89 M |
$9.14 M |
$7.12 M |
$7.72 M |
$6.53 M |
$5.45 M |
$1.29 M |
$1.19 M |
| Interest Income |
$180,000.00 |
$161,000.00 |
$19,000.00 |
$3,739.00 |
$49,915.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$65,493.00 |
| Interest Expense |
$0.00 |
-$263,000.00 |
-$18,709.00 |
-$3,739.00 |
-$49,915.00 |
$6.86 M |
$209,506.00 |
$57,890.00 |
$88,524.00 |
$0.00 |
| Depreciation &
Amortization |
$220,000.00
|
$525,000.00
|
$452,909.00
|
$383,972.00
|
$396,665.00
|
$133,420.00
|
$139,213.00
|
$151,174.00
|
$125,423.00
|
$134,127.00
|
| EBITDA |
-$25.02 M
|
-$24.51 M
|
-$16.75 M
|
-$8.96 M
|
-$6.64 M
|
-$7.40 M
|
-$7.67 M
|
-$4.51 M
|
-$1.16 M
|
-$818,532.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
-212.52 |
-39.68 |
-18.18 |
-5.74 |
0 |
-3.46 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
-245.67
|
-42.11
|
-14.46
|
-5.93
|
0
|
-4.03
|
| Total Other
Income/Expenses Net |
$1.72 M
|
$263,000.00
|
$364,681.00
|
-$360.00
|
$49,915.00
|
$1.35 M
|
$231,414.00
|
-$871,185.00
|
$177.00
|
-$65,493.00
|
| Income Before Tax |
-$23.52 M |
-$24.67 M |
-$16.53 M |
-$9.14 M |
-$7.63 M |
-$13.04 M |
-$7.79 M |
-$5.59 M |
-$1.38 M |
-$1.02 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
-244.07
|
-69.91
|
-18.46
|
-7.11
|
0
|
-4.31
|
| Income Tax Expense |
$0.00 |
-$365,000.00 |
-$331,409.00 |
-$215,546.00 |
$863,542.00 |
$1.67 M |
$209,506.00 |
-$2.14 M |
$314,339.00 |
$0.00 |
| Net Income |
-$23.52 M |
-$24.30 M |
-$16.20 M |
-$8.92 M |
-$7.63 M |
-$13.04 M |
-$7.79 M |
-$3.39 M |
-$1.60 M |
-$1.02 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
-244.07 |
-69.91 |
-18.46 |
-4.31 |
0 |
-4.31 |
| EPS |
-1.91 |
-2.16 |
-1.87 |
-6.91 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
-4.26 |
| EPS Diluted |
-1.91 |
-2.16 |
-1.87 |
-6.91 |
-12.1 |
-34.83 |
-20.1 |
-7.72 |
-3.66 |
-4.24 |
| Weighted Average Shares
Out |
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630,417.00
|
$374,498.00
|
$387,691.00
|
$438,718.00
|
$438,718.00
|
$239,000.00
|
| Weighted Average Shares
Out Diluted |
$12.30 M
|
$11.23 M
|
$8.68 M
|
$1.29 M
|
$630,417.00
|
$374,498.00
|
$387,691.00
|
$438,718.00
|
$438,718.00
|
$240,000.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
